medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2020-18-115-121medsovet-5903Research ArticleАЛЛЕРГОЛОГИЯ И ИММУНОЛОГИЯALLERGOLOGY AND IMMUNOLOGYКлиническая эффективность препарата меполизумаб в терапии тяжелой эозинофильной астмы у детейClinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in childrenhttps://orcid.org/0000-0002-0535-2916ДроздовВ. Н.DrozdovV. N.

д.м.н., профессор, профессор кафедры клинической фармакологии и пропедевтики внутренних болезней

119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Dr. of Sci. (Med.), Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases

8, Bldg. 2, Trubetskaya St., Moscow, 119991, Russia

vndrozdov@yandex.ruhttps://orcid.org/0000-0002-7430-3341АстаповскийА. А.AstapovskiyA. A.

клинический ординатор кафедры клинической фармакологии и пропедевтики внутренних болезней

119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Clinical resident of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases

8, Bldg. 2, Trubetskaya St., Moscow, 119991, Russia

al.astapovskii@gmail.comhttps://orcid.org/0000-0002-7163-7119СереброваС. Ю.SerebrovaS. Yu.

д.м.н., главный научный сотрудник Центра клинической фармакологии; профессор кафедры  клинической фармакологии и пропедевтики внутренних болезней

127051, Россия, Москва, Петровский бульвар, д. 8, стр. 2

119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Dr. of Sci. (Med.), Chief Researcher of Clinical Pharmacology Centre; Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases

8, Bldg. 2, Petrovsky Boulevard, Moscow, 127051, Russia

8, Bldg. 2, Trubetskaya St., Moscow, 119991, Russia

svetaserebrova@mail.ruhttps://orcid.org/0000-0001-6589-7654ШихЕ. В.ShikhE. V.

д.м.н., профессор, заведующая кафедрой клинической фармакологии и пропедевтики внутренних болезней

119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Dr. of Sci. (Med.), Chair of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases

8, Bldg. 2, Trubetskaya St., Moscow, 119991, Russia

chih@mail.ruhttps://orcid.org/0000-0001-5621-2721КомиссаренкоИ. А.KomissarenkoI. A.

д.м.н., профессор кафедры поликлинической терапии

127473, Россия, Москва, ул. Делегатская, д. 20, стр. 1

Dr. of Sci. (Med.), Professor of the Department of Polyclinic Therapy

20, Bldg. 1, Delegateskaya St., Moscow, 127473, Russia

Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияFederal State Autonomous Educational Institution of Higher Education “Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation (Sechenov University)Russian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияFederal State Autonomous Educational Institution of Higher Education “Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation (Sechenov University)Russian FederationФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации; Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияFederal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products”; Federal State Autonomous Educational Institution of Higher Education “Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation (Sechenov University)Russian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of the Higher Education “Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russian FederationRussian Federation202027112020018115121Copyright © Дроздов В.Н., Астаповский А.А., Сереброва С.Ю., Ших Е.В., Комиссаренко И.А., 20202020Дроздов В.Н., Астаповский А.А., Сереброва С.Ю., Ших Е.В., Комиссаренко И.А.Drozdov V.N., Astapovskiy A.A., Serebrova S.Y., Shikh E.V., Komissarenko I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/5903тяжелая бронхиальная астмамеполизумабэозинофилыинтерлейкин-5детиsevere asthmamepolizumabeosinophilsinterleukin-5childrenReferencesVos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196. doi: 10.1016/S0140-6736(12)61729-2.Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196. doi: 10.1016/S0140-6736(12)61729-2.Chuchalin A., Khaltaev N., Antonov N., Galkin D., Manakov L., Antonini P. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9(1):963–974. doi: 10.2147/copd.s67283.Chuchalin A., Khaltaev N., Antonov N., Galkin D., Manakov L., Antonini P. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9(1):963–974. doi: 10.2147/copd.s67283.Авдеев С.Н., Ненашева Н.М., Жуденков К.В., Петраковская В.А., Изюмова Г.В. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации. Пульмонология. 2018;28(3):341–358. doi: 10.18093/0869-0189-2018-28-3-341-358.Avdeev S.N., Nenasheva N.M., Zhudenkov K.V., Petrakovskaya V.A., Izyumova G.V. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya = Russian Pulmonology Journal. 2018;28(3):341–358. (In Russ.) doi: 10.18093/0869-0189-2018-28-3-341-358.Поликарпов А.В., Александрова Г.А., Голубева Н.А., Тюрина Е.М., Оськов Ю.И., Шелепова Е.А. Общая заболеваемость детского населения России (0–14 лет) в 2017 году: cтатистические материалы. Ч. VI. 2018. 144 с. Режим доступа: https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god.https://minzdrav.gov.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/statisticheskiy-sbornik-2017-god.Moore W.С., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X. et al. Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. Am J Respir Critic Care Med. 2010;181(4):315–323. doi: 10.1164/rccm.200906-0896oc.Moore W.С., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X. et al. Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program. Am J Respir Critic Care Med. 2010;181(4):315–323. doi: 10.1164/rccm.200906-0896oc.Chung K.F. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Int Med. 2015;279(2):192–204. doi: 10.1111/joim.12382.Chung K.F. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Int Med. 2015;279(2):192–204. doi: 10.1111/joim.12382.Fitzpatrick A.M., Jackson D.J., Mauger D.T., Boehmer S.J., Phipatanakul W., Sheehan W.J. et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–1618.e12. doi: 10.1016/j.jaci.2016.09.028.Fitzpatrick A.M., Jackson D.J., Mauger D.T., Boehmer S.J., Phipatanakul W., Sheehan W.J. et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–1618.e12. doi: 10.1016/j.jaci.2016.09.028.Guilbert T.W., Bacharier L.B., Fitzpatrick A.M. Severe Asthma in Children. J Allergy Clin Immunol Pract. 2014;2(5):489–500. doi: 10.1016/j.jaip.2014.06.022.Guilbert T.W., Bacharier L.B., Fitzpatrick A.M. Severe Asthma in Children. J Allergy Clin Immunol Pract. 2014;2(5):489–500. doi: 10.1016/j.jaip.2014.06.022.Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2013;43(2):343–373. doi: 10.1183/09031936.00202013.Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2013;43(2):343–373. doi: 10.1183/09031936.00202013.Vottero A., Kino T., Combe H., Lecomte P., Chrousos G.P. A Novel, C-Terminal Dominant Negative Mutation of the GR Causes Familial Glucocorticoid Resistance through Abnormal Interactions with p160 Steroid Receptor Coactivators. J Clin Endocrinol Metab. 2002;87(6):2658–2667. doi: 10.1210/jcem.87.6.8520.Vottero A., Kino T., Combe H., Lecomte P., Chrousos G.P. A Novel, C-Terminal Dominant Negative Mutation of the GR Causes Familial Glucocorticoid Resistance through Abnormal Interactions with p160 Steroid Receptor Coactivators. J Clin Endocrinol Metab. 2002;87(6):2658–2667. doi: 10.1210/jcem.87.6.8520.Israel E., Drazen J.M., Liggett S.B., Boushey H.A., Cherniack R.M., Chinchilli V.M. et al. Effect of Polymorphism of the β(2)-Adrenergic Receptor on Response to Regular Use of Albuterol in Asthma. Int Arch Allergy Immunol. 2001;124(1–3):183–186. doi: 10.1159/000053705.Israel E., Drazen J.M., Liggett S.B., Boushey H.A., Cherniack R.M., Chinchilli V.M. et al. Effect of Polymorphism of the β(2)-Adrenergic Receptor on Response to Regular Use of Albuterol in Asthma. Int Arch Allergy Immunol. 2001;124(1–3):183–186. doi: 10.1159/000053705.Barnes P.J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636–645. doi: 10.1016/j.jaci.2012.12.1564.Barnes P.J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636–645. doi: 10.1016/j.jaci.2012.12.1564.Gagliardo R., Chanez P., Vignola A.M., Bousquet J., Vachier I., Godard P. et al. Glucocorticoid Receptor α and β in Glucocorticoid Dependent Asthma. Am J Respir Crit Care Med. 2000;162(1):7–13. doi: 10.1164/ajrccm.162.1.9911032.Gagliardo R., Chanez P., Vignola A.M., Bousquet J., Vachier I., Godard P. et al. Glucocorticoid Receptor α and β in Glucocorticoid Dependent Asthma. Am J Respir Crit Care Med. 2000;162(1):7–13. doi: 10.1164/ajrccm.162.1.9911032.Gupta A., Sjoukes A., Richards D., Banya W., Hawrylowicz C., Bush A., Saglani S. Relationship between Serum Vitamin D, Disease Severity, and Airway Remodeling in Children with Asthma. Am J Respir Crit Care Med. 2011;184(12):1342–1349. doi: 10.1164/rccm.201107-1239oc.Gupta A., Sjoukes A., Richards D., Banya W., Hawrylowicz C., Bush A., Saglani S. Relationship between Serum Vitamin D, Disease Severity, and Airway Remodeling in Children with Asthma. Am J Respir Crit Care Med. 2011;184(12):1342–1349. doi: 10.1164/rccm.201107-1239oc.Saglani S., Lloyd C.M. Novel concepts in airway inflammation and remodelling in asthma. Eur Respir J. 2015;46(6):1796–1804. doi: 10.1183/13993003.01196-2014.Saglani S., Lloyd C.M. Novel concepts in airway inflammation and remodelling in asthma. Eur Respir J. 2015;46(6):1796–1804. doi: 10.1183/13993003.01196-2014.Bossley C.J., Fleming L., Ullmann N., Gupta A., Adams A., Nagakumar P. et al. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. J Allergy Clin Immunol. 2016;138(2):413–420.e6. doi: 10.1016/j.jaci.2015.12.1347.Bossley C.J., Fleming L., Ullmann N., Gupta A., Adams A., Nagakumar P. et al. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. J Allergy Clin Immunol. 2016;138(2):413–420.e6. doi: 10.1016/j.jaci.2015.12.1347.Hossny E., Rosario N., Lee B.W., Singh M., El-Ghoneimy D., Soh J., Le Souef P. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J. 2016;9:26. doi: 10.1186/s40413-016-0117-0.Hossny E., Rosario N., Lee B.W., Singh M., El-Ghoneimy D., Soh J., Le Souef P. The use of inhaled corticosteroids in pediatric asthma: update. World Allergy Organ J. 2016;9:26. doi: 10.1186/s40413-016-0117-0.Milburn M., Hassell A.M., Lambert M.H., Jordan S.R., Proudfoot A.E., Graber P., Wells T.N. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 1993;363(6425):172–176. doi: 10.1038/363172a0.Milburn M., Hassell A.M., Lambert M.H., Jordan S.R., Proudfoot A.E., Graber P., Wells T.N. A novel dimer configuration revealed by the crystal structure at 2.4 A resolution of human interleukin-5. Nature. 1993;363(6425):172–176. doi: 10.1038/363172a0.Kouro T., Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303–1309. doi: 10.1093/intimm/dxp102.Kouro T., Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303–1309. doi: 10.1093/intimm/dxp102.Dent L.A., Strath M., Mellor A.L., Sanderson C.J. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990;172(5):1425–1431. doi: 10.1084/jem.172.5.1425.Dent L.A., Strath M., Mellor A.L., Sanderson C.J. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med. 1990;172(5):1425–1431. doi: 10.1084/jem.172.5.1425.Azzawi M., Bradley B., Jeffery P.K., Frew A.J., Wardlaw A.J., Knowles G. et al. Identification of Activated T Lymphocytes and Eosinophils in Bronchial Biopsies in Stable Atopic Asthma. Am Rev Respir Dis. 1990;142(6 Pt 1): 1407–1413. doi: 10.1164/ajrccm/142.6_pt_1.1407.Azzawi M., Bradley B., Jeffery P.K., Frew A.J., Wardlaw A.J., Knowles G. et al. Identification of Activated T Lymphocytes and Eosinophils in Bronchial Biopsies in Stable Atopic Asthma. Am Rev Respir Dis. 1990;142(6 Pt 1): 1407–1413. doi: 10.1164/ajrccm/142.6_pt_1.1407.Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996;183(1):195–201. doi: 10.1084/jem.183.1.195.Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996;183(1):195–201. doi: 10.1084/jem.183.1.195.Leckie M.J., ten Brinke A., Khan J., Diamant Z., O’Connor B.J., Walls C.M. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148. doi: 10.1016/s0140-6736(00)03496-6.Leckie M.J., ten Brinke A., Khan J., Diamant Z., O’Connor B.J., Walls C.M. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148. doi: 10.1016/s0140-6736(00)03496-6.Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L. et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. doi: 10.1164/rccm.200701-085oc.Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L. et al. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. doi: 10.1164/rccm.200701-085oc.Powell C., Milan S.J., Dwan K., Bax L., Walters N. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015; (7):CD010834. doi: 10.1002/14651858.cd010834.pub2.Powell C., Milan S.J., Dwan K., Bax L., Walters N. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015; (7):CD010834. doi: 10.1002/14651858.cd010834.pub2.Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A. et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. N Engl J Med. 2009;360(10):973–984. doi: 10.1056/nejmoa0808991.Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A. et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. N Engl J Med. 2009;360(10):973–984. doi: 10.1056/nejmoa0808991.Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E. et al. Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. N Engl J Med. 2009;360(10):985–993. doi: 10.1056/nejmoa0805435.Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E. et al. Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. N Engl J Med. 2009;360(10):985–993. doi: 10.1056/nejmoa0805435.Pavord I., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi: 10.1016/s0140-6736(12)60988-x.Pavord I., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi: 10.1016/s0140-6736(12)60988-x.Bel E.H., Wenzel S.E., Thompson P.J., Prazma C.M., Keene O.N., Yancey S.W. et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med. 2014;371(13):1189–1197. doi: 10.1056/nejmoa1403291.Bel E.H., Wenzel S.E., Thompson P.J., Prazma C.M., Keene O.N., Yancey S.W. et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Engl J Med. 2014;371(13):1189–1197. doi: 10.1056/nejmoa1403291.Ortega H.G., Liu M.C., Pavord I.D., Brusselle G.G., FitzGerald J.M., Chetta A. et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med. 2014;371(13):1198–1207. doi: 10.1056/nejmoa1403290.Ortega H.G., Liu M.C., Pavord I.D., Brusselle G.G., FitzGerald J.M., Chetta A. et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N Engl J Med. 2014;371(13):1198–1207. doi: 10.1056/nejmoa1403290.Ferguson G., FitzGerald J.M., Bleecker E.R., Laviolette M., Bernstein D., LaForce C. et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568–576. doi: 10.1016/s2213-2600(17)30190-x.Ferguson G., FitzGerald J.M., Bleecker E.R., Laviolette M., Bernstein D., LaForce C. et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568–576. doi: 10.1016/s2213-2600(17)30190-x.Varricchi G., Bagnasco D., Ferrando M., Puggioni F., Passalacqua G., Canonica G.W. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. 2017;11(1):40–45. doi: 10.1177/1753465816673303.Varricchi G., Bagnasco D., Ferrando M., Puggioni F., Passalacqua G., Canonica G.W. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. 2017;11(1):40–45. doi: 10.1177/1753465816673303.Tsukamoto N., Takahashi N., Itoh H., Pouliquen I. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. Clin Pharmacol Drug Dev. 2016;5(2):102–108. doi: 10.1002/cpdd.205.Tsukamoto N., Takahashi N., Itoh H., Pouliquen I. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. Clin Pharmacol Drug Dev. 2016;5(2):102–108. doi: 10.1002/cpdd.205.Pouliquen I.J., Kornmann O., Barton S.V., Price J.A., Ortega H.G. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015–1027. doi: 10.5414/cp202446.Pouliquen I.J., Kornmann O., Barton S.V., Price J.A., Ortega H.G. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015–1027. doi: 10.5414/cp202446.Licari A., Manti S., Castagnoli R., Parisi G.F., Salpietro C., Leonardi S., Marseglia G.L. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatric Drugs. 2019;21(4):215–237. doi: 10.1007/s40272-019-00345-7.Licari A., Manti S., Castagnoli R., Parisi G.F., Salpietro C., Leonardi S., Marseglia G.L. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatric Drugs. 2019;21(4):215–237. doi: 10.1007/s40272-019-00345-7.Logan J.K., Harinstein L., Muñoz M. Pediatric Postmarketing Pharmacovigilance Review: Cinqair (Reslizumab). Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM610723.pdf.Logan J.K., Harinstein L., Muñoz M. Pediatric Postmarketing Pharmacovigilance Review: Cinqair (Reslizumab). Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM610723.pdf.Corren J., Weinstein S., Janka L., Zangrilli J., Garin M. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest. 2016;150(4):799–810. doi: 10.1016/j.chest.2016.03.018.Corren J., Weinstein S., Janka L., Zangrilli J., Garin M. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest. 2016;150(4):799–810. doi: 10.1016/j.chest.2016.03.018.Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi: 10.1016/s0140-6736(16)31324-1.Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi: 10.1016/s0140-6736(16)31324-1.Gupta A., Pouliquen I., Austin D., Price R.G., Kempsford R., Steinfeld J. et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019;54(12):1957–1967. doi: 10.1002/ppul.24508.Gupta A., Pouliquen I., Austin D., Price R.G., Kempsford R., Steinfeld J. et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019;54(12):1957–1967. doi: 10.1002/ppul.24508.

The authors declare that there are no conflicts of interest present.